Early downregulation of hsa-miR-144-3p in serum from drug-naïve Parkinson’s disease patients

Elisa Zago, Alessandra Dal Molin, Giovanna Maria Dimitri, Luciano Xumerle, Chiara Pirazzini, Maria Giulia Bacalini, Maria Giovanna Maturo, Tiago Azevedo, S Spasov, Pilar Gómez‐Garre, María Teresa Periñán, Silvia Jesús, Luca Baldelli, Luisa Sambati, Giovanna Calandra–Buonaura, Paolo Garagnani, Federica Provini, Pietro Cortelli, Pablo Mir, Claudia Trenkwalder, Brit Mollenhauer, Claudio Franceschi, Píetro Lió, Christine Nardini, Astrid Adarmes‐Gómez, Anna Bartoletti‐Stella, Kailash P. Bhatia, Marta Bonilla‐Toribio, Claudia Boninsegna, Marcella Broli, Dolores Buiza‐Rueda, Sabina Capellari, Mario Carrión‐Claro, Rosalia Cilea, Robert Clayton, Silvia De Luca, Patrizia De Massis, Ivan Doykov, Rocio Escuela-Martin, Giovanni Fabbri, A. S. Gabellini, Cristina Giuliani, Pietro Guaraldi, Sara Hägg, Jenny Hällqvist, Claire Halsband, Wendy Heywood, Henry Houlden, Ismae Huertas, Juulia Jylhävä, Miguel A. Labrador‐Espinosa, Cristina Licari, Claudio Luchinat, Daniel Macías, S. Macrì, Francesca Magrinelli, Juan Francisco Martín Rodríguez, Delledonne Massimo, Giacomo Mengozzi, Gaia Meoni, Francesco Mignani, Maddalena Milazzo, Kevin Mills, Stefania Alessandra Nassetti, Nancy L. Pedersen, María Teresa Periñán-Tocino, Francesco Ravaioli, Claudia Sala, Sebastian Schade, Sebastian R. Schreglmann, Stephen C. Strom, Cristina Tejera‐Parrado, Leonardo Tenori, Paola Turano, Franco Valzania, Rosario Vigo Ortega, Dylan M. WilliamsScientific 2022 · DOI

TL;DR

This study identifies hsa-miR-144-3p as a potential early biomarker for Parkinson's Disease (PD) by observing its consistent downregulation in the serum of drug-naïve PD patients. Further analysis suggests this microRNA plays a role in regulating coagulation, a process known to be disrupted in PD, opening avenues for early diagnosis and understanding disease mechanisms.

What Problem Does This Paper Address?

Parkinson's Disease (PD) is a complex neurodegenerative disorder where aging is a primary risk factor. While microRNAs (miRNAs) are known to be involved in aging processes and have emerged as potential biomarkers, their specific role in the interplay between aging and PD pathogenesis, particularly in the early stages of the disease, remains unclear. Existing studies often focus on advanced PD patients, whose miRNA profiles might be influenced by drug treatments or disease progression. This paper aims to bridge this gap by investigating miRNAs in drug-naïve PD patients within the context of aging, seeking to identify early diagnostic markers and understand their functional relevance.

Methods

The researchers employed a multi-stage approach:

  • Next-Generation Sequencing (NGS): Serum samples from a discovery cohort (drug-naïve PD patients, healthy controls, and centenarians) were analyzed using NGS to profile miRNA expression.
  • Differential Expression Analysis: Statistical methods (DESeq2) were used to identify miRNAs with significantly different expression levels between groups.
  • Network Reconstruction (ARACNE): To understand miRNA interactions, the ARACNE algorithm was used to build miRNA co-expression networks. This was followed by community detection (Louvain algorithm) to identify groups of interacting miRNAs.
  • Quantitative RT-PCR (qPCR): This is a standard validation technique used to confirm the expression levels of candidate miRNAs identified by NGS.
  • Functional Analysis: Tools like MiRTarBase, HMDD3.2, and MIENTURNET were used to predict and analyze miRNA targets, their involvement in biological pathways (KEGG, Reactome), and their association with diseases.

Datasets

The study utilized serum samples from several cohorts:

  • Discovery Cohort:
    • Drug-naïve Parkinson's Disease (dnPD) patients (n=61)
    • Healthy Controls (CTR) (n=77, split between GOE and UNIBO sites)
    • Centenarians (CENT) (n=27)
  • Validation Cohort:
    • Advanced Parkinson's Disease (adPD) patients (n=12)
    • Drug-naïve Parkinson's Disease (dnPD) patients (n=144)
    • Parkinson's Disease siblings (PDsibs) (n=48)
    • Healthy Controls (CTR) from the discovery cohort were used as a reference.

The NGS data has been deposited in the NCBI's Gene Expression Omnibus (GEO) under accession number GSE180193.

Key Insights and Ideas

  • hsa-miR-144-3p as an Early PD Biomarker: The most significant finding is the consistent downregulation of hsa-miR-144-3p in early, drug-naïve PD patients. This suggests it could serve as an early indicator of the disease, potentially predating more overt symptoms or drug interventions.
  • Coagulation Pathway Involvement: Functional analysis revealed that hsa-miR-144-3p is implicated in the regulation of the complement and coagulation cascades. This is particularly interesting because alterations in blood coagulation are increasingly recognized as a feature of PD.
  • Ageing and PD Disconnect: Interestingly, the study did not find strong evidence of miRNAs being co-regulated in both Parkinson's Disease and general ageing processes, challenging a simple direct link in serum miRNA profiles.
  • Network Analysis Reveals miRNA Communities: The network analysis highlighted that several differentially expressed miRNAs, including hsa-miR-144-3p, cluster together in specific communities within the dnPD cohort. This suggests coordinated biological functions among these miRNAs.

Key Results

  • Differential Expression: hsa-miR-144-3p was consistently found to be significantly downregulated in drug-naïve PD patients compared to controls. This finding was robustly confirmed through both NGS and subsequent qPCR validation.
  • Validation Cohort Results: The downregulation trend of hsa-miR-144-3p was also observed in advanced PD patients and in PD siblings (a population at higher genetic risk), although the magnitude of change varied.
  • Other miRNAs: While hsa-miR-150-5p and hsa-miR-215-5p also showed differential expression in the discovery phase, their trends in the validation cohort were different from the initial findings, leading the researchers to focus exclusively on hsa-miR-144-3p. hsa-miR-122-5p was found to be specific to the CENT vs CTR contrast.
  • Functional Annotation: Targets of hsa-miR-144-3p were enriched in pathways related to platelet function and coagulation.

Limitations and Future Work

  • Limited Magnitude in Advanced Stages: While hsa-miR-144-3p showed a downregulation trend in adPD and PDsibs, the magnitude of this change was less pronounced than in dnPD. This suggests its role might be more prominent in the early stages or that other factors influence its levels later in the disease.
  • Functional Details Unclear: The paper acknowledges that further research is needed to fully elucidate the precise functional mechanisms by which hsa-miR-144-3p influences coagulation and its specific role in PD pathogenesis.
  • Ageing vs. PD Specificity: The lack of strong miRNA co-regulation between general ageing and PD in serum suggests that the observed changes in PD might be more disease-specific rather than solely age-driven. Future work could explore other biological compartments or more specific aging markers.
  • Translational Potential: The authors suggest that hsa-miR-144-3p could be an early marker for PD, emphasizing the need for further research to validate its diagnostic and prognostic potential. Investigating its role in preventing or slowing disease progression is also a key future direction.

Summary updated

Abstract

Advanced age represents one of the major risk factors for Parkinson's Disease. Recent biomedical studies posit a role for microRNAs, also known to be remodelled during ageing. However, the relationship between microRNA remodelling and ageing in Parkinson's Disease, has not been fully elucidated. Therefore, the aim of the present study is to unravel the relevance of microRNAs as biomarkers of Parkinson's Disease within the ageing framework. We employed Next Generation Sequencing to profile serum microRNAs from samples informative for Parkinson's Disease (recently diagnosed, drug-naïve) and healthy ageing (centenarians) plus healthy controls, age-matched with Parkinson's Disease patients. Potential microRNA candidates markers, emerging from the combination of differential expression and network analyses, were further validated in an independent cohort including both drug-naïve and advanced Parkinson's Disease patients, and healthy siblings of Parkinson's Disease patients at higher genetic risk for developing the disease. While we did not find evidences of microRNAs co-regulated in Parkinson's Disease and ageing, we report that hsa-miR-144-3p is consistently down-regulated in early Parkinson's Disease patients. Moreover, interestingly, functional analysis revealed that hsa-miR-144-3p is involved in the regulation of coagulation, a process known to be altered in Parkinson's Disease. Our results consistently show the down-regulation of hsa-mir144-3p in early Parkinson's Disease, robustly confirmed across a variety of analytical and experimental analyses. These promising results ask for further research to unveil the functional details of the involvement of hsa-mir144-3p in Parkinson's Disease.
BibTeX
@inproceedings{zago2022early,
  author = {Elisa Zago and Alessandra Dal Molin and Giovanna Maria Dimitri and Luciano Xumerle and Chiara Pirazzini and Maria Giulia Bacalini and Maria Giovanna Maturo and Tiago Azevedo and S Spasov and Pilar Gómez‐Garre and María Teresa Periñán and Silvia Jesús and Luca Baldelli and Luisa Sambati and Giovanna Calandra–Buonaura and Paolo Garagnani and Federica Provini and Pietro Cortelli and Pablo Mir and Claudia Trenkwalder and Brit Mollenhauer and Claudio Franceschi and Píetro Lió and Christine Nardini and Astrid Adarmes‐Gómez and Tiago Azevedo and Maria Giulia Bacalini and Luca Baldelli and Anna Bartoletti‐Stella and Kailash P. Bhatia and Marta Bonilla‐Toribio and Claudia Boninsegna and Marcella Broli and Dolores Buiza‐Rueda and Giovanna Calandra–Buonaura and Sabina Capellari and Mario Carrión‐Claro and Rosalia Cilea and Robert Clayton and Pietro Cortelli and Alessandra Dal Molin and Silvia De Luca and Patrizia De Massis and Giovanna Maria Dimitri and Ivan Doykov and Rocio Escuela-Martin and Giovanni Fabbri and Claudio Franceschi and A. S. Gabellini and Paolo Garagnani and Cristina Giuliani and Pilar Gómez‐Garre and Pietro Guaraldi and Sara Hägg and Jenny Hällqvist and Claire Halsband and Wendy Heywood and Henry Houlden and Ismae Huertas and Silvia Jesús and Juulia Jylhävä and Miguel A. Labrador‐Espinosa and Cristina Licari and Píetro Lió and Claudio Luchinat and Daniel Macías and S. Macrì and Francesca Magrinelli and Juan Francisco Martín Rodríguez and Delledonne Massimo and Maria Giovanna Maturo and Giacomo Mengozzi and Gaia Meoni and Francesco Mignani and Maddalena Milazzo and Kevin Mills and Pablo Mir and Brit Mollenhauer and Christine Nardini and Stefania Alessandra Nassetti and Nancy L. Pedersen and María Teresa Periñán-Tocino and Chiara Pirazzini and Federica Provini and Francesco Ravaioli and Claudia Sala and Luisa Sambati and Píetro Lió and Sebastian Schade and Sebastian R. Schreglmann and S Spasov and Stephen C. Strom and Cristina Tejera‐Parrado and Leonardo Tenori and Claudia Trenkwalder and Paola Turano and Franco Valzania and Rosario Vigo Ortega and Dylan M. Williams and Luciano Xumerle},
  title = {{Early downregulation of hsa-miR-144-3p in serum from drug-naïve Parkinson’s disease patients}},
  booktitle = {Scientific},
  year = {2022},
  doi = {10.1038/s41598-022-05227-6},
}
Figure